Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

Caitlin MurphyAndrea MuscatDavid AshleyViolet MukaroLinda WestYang LiaoDavid ChisangaWei ShiIan M CollinsSally Baron-HaySujata PatilGeoffrey LindemanMustafa Khasraw

Published in: PloS one (2019)

Clinicaltrials.gov NCT01830244.

Keyphrases

phase ii
clinical trial
open label
phase iii
rectal cancer
lymph node
low dose
placebo controlled
locally advanced
high dose
double blind
smoking cessation
study protocol
single molecule
iron oxide
radiation therapy
randomized controlled trial
chemotherapy induced
breast cancer risk